IntroducingKabiCare

A resource designed to support patients receiving IDACIO▼ (adalimumab) and their healthcare professionals

Help us direct you to the right information by selecting one of the following options. You will need to register to access the full content. Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional.

PATIENT RECEIVING IDACIO

Only for patients prescribed IDACIO
If you have not been prescribed IDACIO, please access the Member of the general public part of this website.

Only for healthcare professionals

Only for healthcare professionals. By entering this part of the site you are confirming you are a healthcare professional. Contains brand information.

Member of the General Public

For the general public.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (for UK residents) or see http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.

KabiCare has been developed and funded by Fresenius Kabi Ltd. IDACIO is a registered trademark of Fresenius Kabi Ltd.

023/KABICARE/FKUK-IRL August 2020